Illumina has reported robust revenue growth, with sales increasing by 38.1% year-over-year in the most recent quarter. The company's net margin has also expanded significantly, rising from 29.4% a year ago to 31.7% in the latest quarter. This margin expansion reflects Illumina's ability to maintain pricing power and control costs, despite the rapid growth. Illumina's dominant market share, currently at over 70%, underscores its competitive advantage in the genetic sequencing market. The company's leading technology and extensive intellectual property portfolio create high barriers to entry, allowing Illumina to maintain its industry leadership. Illumina's return on invested capital (ROIC) has remained elevated at 18.5%, indicating efficient capital allocation and strong profitability. Looking ahead, I expect Illumina to continue capitalizing on the growing demand for genetic analysis, with revenue growth accelerating to 15-20% over the next 12-18 months. Coupled with further margin expansion, this should drive EPS growth of 20-25%, supporting a potential share price appreciation of 30-40% from the current level of $350. Illumina currently trades at a forward P/E ratio of 25x, which appears reasonable given the company's strong competitive positioning and growth prospects. PORTFOLIO ROTATION: SELL: BUY:

Research these companies